Scenic Biotech Appoints Oscar Izeboud as Chief Executive Officer

Amsterdam, The Netherlands, 1 July 2020 – Scenic Biotech BV (“Scenic”), a pioneer in the discovery of genetic modifiers to enable the development of disease modifying therapeutics for rare genetic disorders and other devastating illnesses, today announced that...

BioGeneration Ventures closes BGV IV fund at €105 million

Investors include Bristol Myers Squibb, European Investment Fund, Industriens Pension, KfW Capital, Schroder Adveq   Investment focus on entrepreneurial innovation in therapeutics in Europe Total assets under management >€220 million ($250m) Naarden, The...